Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept plus glucocorticoids vs glucocorticoids in IgG4-related disease
ChiCTR2500101050Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of telitacicept in IgG4-related disease (IgG4-RD) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Clinical response rate at 24 weeks. Started Apr 2025; status: recruiting.
02
Drugs
telitacicept
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on ChiCTR2500101050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101050.